drugset / Trial / NCT06932523
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).
Timeline
- Start
- 2025-04-04
- Primary completion
- 2026-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant herpes zoster vaccine with high-dose adjuvant | Vaccine | — | Intramuscular |
| Subject | Recombinant herpes zoster vaccine with low-dose adjuvant | Vaccine | — | Intramuscular |
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | Intramuscular |